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Abstract
Deregulated expression of the type I cytokine receptor, CRLF2, is observed in 5–15% of precursor
B-cell acute lymphoblastic leukaemia (B-ALL). We aimed to determine the clinical and genetic land-
scape of those with IGH-CRLF2 or P2RY8-CRLF2 (CRLF2-r) using multiple genomic approaches.
Clinical and demographic features of CRLF2-r patients were characteristic of B-ALL. Patients with
IGH-CRLF2 were older (14 y vs. 4 y, P< .001), while the incidence of CRLF2-r among Down syn-
drome patients was high (50/161, 31%). CRLF2-r co-occurred with primary chromosomal
rearrangements but the majority (111/161, 69%) had B-other ALL. Copy number alteration (CNA)
proﬁles were similar to B-other ALL, although CRLF2-r patients harbored higher frequencies of
IKZF1 (60/138, 43% vs. 77/1351, 24%) and BTG1 deletions (20/138, 15% vs. 3/1351, 1%). There
were signiﬁcant diﬀerences in CNA proﬁles between IGH-CRLF2 and P2RY8-CRLF2 patients:
IKZF1 (25/35, 71% vs. 36/108, 33%, P< .001), BTG1 (11/35, 31% vs. 10/108, 9%, P 5.004), and
ADD3 deletions (9/19, 47% vs. 5/38, 13%, P 5.008). A novel gene fusion, USP9X-DDX3X, was dis-
covered in 10/54 (19%) of patients. Pathway analysis of the mutational proﬁle revealed novel
involvement for focal adhesion. Although the functional relevance of many of these abnormalities
are unknown, they likely activate additional pathways, which may represent novel therapeutic
targets.
1 | INTRODUCTION
Acute lymphoblastic leukaemia (ALL) is deﬁned by primary chromosomal
abnormalities that drive disease progression, with impact on prognosis
and treatment stratiﬁcation.1 One quarter of patients, known as B-other
ALL, lack a known primary abnormality.1 A group of B-other patients,
known as Ph-like/BCR-ABL1-like, constitute 10–15% of B-ALL. Although
they lack the BCR-ABL1 fusion, their gene expression proﬁle is similar to
BCR-ABL1 positive ALL.2,3 They are characterised by high expression of
the type I cytokine receptor, cytokine receptor-like factor 2 (CRLF2), the
presence of tyrosine kinase fusion genes and mutations of genes within
the JAK/STAT and RAS signaling pathways.4 Deregulated expression of
CRLF2 (CRLF2-d) is observed in 27–50% of patients with BCR-ABL1-like
disease (5–15% of B-ALL).1,4–6 Deregulation occurs via three genomic
rearrangements (CRLF2-r): a cryptic reciprocal translocation with the
immunoglobulin heavy chain locus (IGH); an interstitial deletion within
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the pseudoautosomal region (PAR1) of chromosomes X and Y (P2RY8-
CRLF2); rare but recurrent CRLF2 mutations. All three CRLF2-r result in
overexpression of CRLF2 mRNA and protein; however, alone they are
insuﬃcient to cause overt leukaemia.5,7 Interestingly, studies identifying
CRLF2-d patients by mRNA and protein expression have shown that
some patients do not harbor one of the three known genomic rearrange-
ments.8 The cause of this overexpression is currently unknown. The inci-
dence of CRLF2-r is high in patients with Down syndrome ALL (DS-ALL)
(>50%) and intrachromosomal ampliﬁcation of chromosome 21
(iAMP21) (25%),5,7,9211 with other established cytogenetic abnormalities
rarely associated. However, data indicating whether CRLF2-r is a primary
or secondary event are scarce.12 It is well documented that deletions of
genes involved in B-cell diﬀerentiation and cell cycle control are recurrent
in these patients.5,13–15 Mutations of the Janus kinase family, in particular
JAK2, and mutations of IL7R, are also recurrently observed and together
result in IL-3 independent growth of mouse BaF3 cells.11,16 Recently,
mutations aﬀecting other kinase genes have also been reported in
CRLF2-d ALL.4,17 Both BCR-ABL1-like and CRLF2-d ALL have been asso-
ciated with poor outcome and increased risk of relapse.2,3,10 Although
MRD-directed treatment intensiﬁcation improves survival,18 outcome for
CRLF2-d ALL remains less favorable than for patients with good risk cyto-
genetics. Hence, novel therapeutic strategies are required to improve sur-
vival and quality of life. In this study, we have explored the clinical and
genetic landscape of patients with known CRLF2 rearrangements. The
aims of this study were: (1) to identify the clinical and genomic diﬀeren-
ces that may exist between patients with IGH or P2RY8 driven overex-
pression of CRLF2; (2) to undertake pathway analysis of whole genome
(WGS) and whole exome sequencing (WES) data to highlight additional
pathways that may co-operate with rearrangements of CRLF2.
2 | MATERIALS AND METHODS
2.1 | Patient samples
We identiﬁed 172 patients with CRLF2-r ALL by ﬂuorescence in situ
hybridisation (FISH) and multiplex ligation-dependent probe ampliﬁca-
tion (MLPA) from the following trials: UKALL97/99 (n568),
UKALL2003 (n575), UKALLXI (n56), and UKALLXII (n526) (Sup-
porting Information Table 1). The patients included in this study were
identiﬁed by screening for CRLF2-r6,14,19–21 and were representative of
the trial. Demographic and clinical details were collected by the Clinical
Trial Service Unit (CTSU, Oxford University, UK). Each contributing
centre obtained relevant ethical approval. Informed consent was
obtained in accordance with the Declaration of Helsinki. Diagnostic
immunophenotypes were collected centrally with review of original
reports for 50 patients (Supporting Information Table 2).
2.2 | Cytogenetics and ﬂuorescence in situ
hybridisation
For details on genetic testing, see Supporting Information Figure 1.
Karyotype data were collected from UK cytogenetics laboratories (Sup-
porting Information Table 1). Cytogenetic analysis and FISH were carried
out on the same diagnostic patient samples. The involvement of IGH was
determined using the LSI IGH Dual Color Break-Apart Rearrangement
Probe (Abbott Molecular, Green Oaks, IL).6,22 Additional FISH probes
used in this study are shown in Supporting Information Table 3. Five con-
trol slides of ﬁxed cells from normal individuals were hybridised with all
probe combinations5 (Supporting Information Table 3) to determine the
cut-oﬀ percentages for false positive results (6 3 3 standard deviations).
A minimum of 100 nuclei were scored by eye for each FISH test by two
independent analysts. When combining three or more ﬂorophores, cap-
ture and scoring was carried out using an automated Olympus BX-61 8-
bay stage ﬂorescence microscope. Images were analysed using the Cyto-
Vision 7.1 SPOT counting system (Leica Microsystems, Gateshead, UK).
2.3 | Multiplex ligation-dependent probe ampliﬁcation
Copy number alterations (CNA) were investigated (n5154) by MLPA
using the SALSA MLPA kit P335 (MRC Holland, Amsterdam, Nether-
lands) according to manufacturer’s guidelines as previously reported.15
2.4 | Aﬀymetrix genome-wide human SNP6.0 array
Suﬃcient material was available from 26 (representitive for cohort)
CRLF2-r patients (15 with matched germ-line sample) for Aﬀymetrix
Genome-Wide Human SNP6.0 analysis, performed by AROS Applied
Biotechnology A/S (Aarhus, Denmark). Copy number alterations were
analysed using Genotyping Console (Aﬀymetrix software) with addi-
tional manual curation (GEO accession number GSE83272).
2.5 | Low depth paired-end and whole exome
sequencing
Suﬃcient diagnostic DNA was available from 11 CRLF2-r patients (repre-
sentitive of cohort and all patients have SNP analysis completed), which
was prepared for library construction (300–500 bp), ﬂow cell preparation
and cluster formation using the Illumina no-PCR library protocol (Illumina
Inc, San Diego, CA), and 50 bp reads were performed using the Illumina
Genome Analyzer IIx instrument following the manufactures guidelines.
Structural variants were selected as previously reported.23
Suﬃcient diagnostic and germ-line DNA from the same 11 patients
was prepared for Illumina paired-end sequencing with subsequent
exome enrichment using the Agilent SureSelect Human All Exon 50 MB
kit (Agilent Technologies LTD, Berkshire, UK). Guidelines for the Illumina
Genome Analyzer IIx instrument were followed for ﬂow-cell preparation,
cluster generation and paired-end sequencing of 75 bp reads.23,24 Whole
†These authors contributed equally to this study.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-
vided the original work is properly cited.
VC 2017 Wiley Periodicals, Inc.
364 | RUSSELL ET AL.
genome and exome sequencing data are available using EGA accession
numbers EGAD00001002007 and EGAD00001002008, respectively.
2.6 | Structural variant detection and validation
Sequencing reads were mapped to the human genome (hg19) with a
minimum and mean fold coverage of 5.61 and 8.46, respectively. The
algorithm BRASS25 was used to identify groups of 2 discordantly
mapped (distance or orientation) paired-end reads. Rearrangements
observed in 5 or more paired-end reads were validated (excluding
those where both reads were in the same intron or outside the coding
regions) by conventional PCR and Sanger sequencing using diagnostic
and remission DNA. If a rearrangement failed to validate using two sets
of primers, repeated twice over a temperature gradient, it was regarded
as a fail. Breakpoints within immunoglobulin loci were not validated.
MLPA and SNP data were also used to validate CNA. A total of 476 SV
were identiﬁed from WGS of 11 patients with CRLF2-r ALL (average
43 SV/patient, range 22–90), including 416 intrachromosomal and 57
interchromosomal rearrangements.
2.7 | Mutation and in/del detection and validation
A total of 458 SNVs and insertion/deletions (in/dels) were identiﬁed
from the same 11 patients. A minimum sequencing coverage of 30-fold
was required for each sample. Default setting of BWA24 and CaVEMan
was used to align the reads and detect somatically acquired single
nucleotide substitutions as previously reported23. The algorithm PIN-
DEL26 was used to detect in/dels.23 Conventional PCR was used to
validate the substitutions, with subsequent 454 pyrosequencing for
conﬁrmation.23 Conventional PCR validated the in/dels, with subse-
quent sequencing using the ABI terminator Cycle Sequencing Kit
(Applied Biosystems) to conﬁrm each in/del.23
2.8 | Targeted JAK mutation screening
Primers were used to amplify exon 14 of the JAK2 and JAK1 genes
only27 and Sanger sequencing conﬁrmed the presence of the mutation.
As far as we are aware CRLF2 mutations have not been reported in
patients with IGH-CRLF2 or P2RY8-CRLF2, therefore screening for
these mutations was not carried out.
2.9 | Statistical analysis
The distribution of categorical variables was examined using Fisher’s
exact test. Due to the investigative nature of this analysis, we did not
apply stringent multiple comparisons adjustment (all tests were con-
ducted at the 5% signiﬁcance level). All analyses were performed using
Intercooled Stata 14.1 for Windows (Stata Corporation, College Sta-
tion, TX).
2.10 | Pathway analysis
Pathway mapping was performed on a defective gene list identiﬁed for
each sample. A gene was considered to be defective if: (1) it contained
at least one nonsilent mutation, (2) was located at the break point junc-
tion of the identiﬁed structural variants, and (3) was located within a
defective region (detected either from SNP6 or WGS) of no more than
1 MB in size. Gene lists from the defective regions were retrieved from
Human reference genome hg19 via biomart28 and defective gene lists
were mapped to KEGG pathways29 using R/Bioconductor package
KEGGREST (Tenenbaum D. KEGGREST: Client-side REST access to
KEGG. R package version 1.11.0). Pathway enrichment analysis was
determined using hypergeometric test. The test is based on the proba-
bility of observing x number of genes from a given pathway as being
defective, given a process of sampling without replacement of all
protein-coding genes (20805) annotated in the human genome
(GRCh37.p13, INSDC Assembly GCA_000001405.14, Feb 2009). This
gene list is considered as a representative gene set that are mutated
among CRLF2-r cases. The basic assumption for the analysis is that
mutations among CRLF2-r cases arise randomly, so the enrichment test
is used as a statistical method to test whether there is any selective
pressure that makes mutations occur in particular pathways more often
than expect by chance. Enrichment tests were performed with the
defective gene lists from all samples as well as for each subtype
separately.
3 | RESULTS
3.1 | The clinical and demographic features of CRLF2-r
patients are characteristic of B-ALL
All patients with CRLF2-r were B-ALL (n5172): IGH-CRLF2 (n547)
and P2RY8-CRLF2 (n5125), median age 5 years (range 1–60 y), male
predominance (59%), 70% had WBC <503 106/l (Supporting Informa-
tion Table 4; Figure 1A). The age distribution was similar to B-ALL
overall, with the majority <10 years (71%).20 Median age (4 y vs. 14 y,
P< .001), WBC (25% vs. 43% with WBC >50 3 106/l, P5 .016) and
percentage NCI high risk (38% vs. 77%, P< .001) diﬀered signiﬁcantly
between P2RY8-CRLF2 and IGH-CRLF2, respectively (Supporting Infor-
mation Table 4; Figure 1A). We conﬁrmed the high frequency of DS-
ALL among CRLF2-r ALL (31%, 50/161) (DS status not available for 11
patients), with more DS-ALL patients harboring the P2RY8-CRLF2
fusion (P2RY8-CRLF2, n541 vs. IGH-CRLF2 n59, 35% vs. 20%,
respectively, P5 .087) (Supporting Information Table 4; Figure 1B).
Cytogenetic analysis was successful in 160 CRLF2-r patients. Nor-
mal karyotype was observed in 51 (36%) patients. The majority, includ-
ing those with DS-ALL, were classiﬁed as B-other ALL (Figure 1B,C);
however, primary, established chromosomal abnormalities co-occurred
in 22% (Supporting Information Table 1): ETV6-RUNX1 (n53), BCR-
ABL1 (n55), high hyperdiploidy (n512), and iAMP21 (n517). All but
one of these patients had P2RY8-CRLF2 (n536) (Figure 1B). No
patients had t(1;19)(q23;p13), KMT2A (MLL) rearrangements or ABL-
class fusions involving ABL1, ABL2, PDGFRB, and CSF1R.4,30,31
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3.2 | Additional chromosomal abnormalities in CRLF2-
r patients
Recurrent somatic structural and numerical aberrations were present in
109 patients (Supporting Information Figure 2), including gains of chro-
mosomes X (37/83, 45%), 21 (13/83, 16%), 17 (7/83, 8%), and 9 (4/83,
5%), in patients with and without DS. The gain of chromosome X was
signiﬁcantly enriched in CRLF2-r patients, particularly among DS-ALL,
when compared to a cohort of B-other patients, where only 5 of 1019
(5%) patients had gain of X (Supporting Information Table 5; Figure 1C).
Copy number alterations (CNA) were detected among patients
with CRLF2-r ALL by MLPA (n5154) and SNP6.0 arrays (n526) (Table
1; Supporting Information Table 1 and 6-7; Figure 1B). Deletions of
IKZF1, CDKN2A/B, PAX5, and BTG1 were present in 43% (n560), 38%
(n552), 30% (n541), and 14% (n520) of cases, respectively. Dele-
tions of IKZF1 and BTG1 occurred at higher incidences than seen in B-
other ALL at 23% and 2%, respectively.21 Deletions of IKZF1 (71% vs.
33% P< .001) and BTG1 (31% vs. 9%, P5 .004) were more frequent in
IGH-CRLF2 than P2RY8-CRLF2 patients, respectively (Figure 1B). There
was a lower incidence of PAX5 and IKZF1 deletions in patients with
DS-associated CRLF2-r ALL compared to those without DS (18% vs.
35% P< .047 and 23% vs. 53%, P5 .003, respectively) (Figure 1C, Sup-
porting Information Table 5). In fact, CRLF2-r DS patients were more
likely to have none of these deletions (48% vs. 15%, P< .001), with
89% (39/44) having fewer than three gene deletions.
Other recurrent CNA observed from SNP6.0 arrays included: the
histone cluster at 6p22.2 (n57), VPREB1 (n56), ADD3 (n55), BTLA
(n54), SLX4IP (n53), SERP2 and TSC22D1 (n53), and PBX3 (n52).
Publically available SNP6.0 data32 showed these deletions to be pres-
ent in other ALL subtypes: ADD3, n59 (4.69%), SLX4IP, n59 (4.69%),
BTLA, n513 (6.77%). To verify their frequency in CRLF2-r ALL, we
screened additional samples by FISH, as ﬁxed cells were the most
abundant source of patient material, that also allowed detection of low
level populations. However, the resolution of FISH restricted accurate
detection of deletions <40 kb. Combined FISH and SNP6.0 data gener-
ated incidences of; ADD3 (14/57, 25%), SLX4IP (13/44, 30%), SERP2
and TSC22D1 (7/55, 13%), and PBX3 (16/56, 29%), with no diﬀerence
in the prevalence between DS and non-DS CRLF2-r ALL. IGH-CRLF2
patients had a higher incidence of ADD3 deletions (46% vs. 13%, IGH
vs. P2RY8, P5 .008) (Supporting Information Table 6; Figure 1B).
3.3 | A novel fusion between USP9X and DDX3X
An interstitial deletion of chromosome sub-band Xp11.4, fusing USP9X
to DDX3X (Supporting Information Figure 3A), was observed in 2/26
cases by SNP6.0 arrays and 7/24 cases by FISH, including one DS
patient, giving an incidence of 19% (Supporting Information Figure 3B).
No cases were identiﬁed among the publically available SNP6.0 data.32
FISH revealed that the fusion was present in both minor and major
clones (8-91% of nuclei) in both male (n54) and female patients
(n55). All male patients had either an additional copy of normal chro-
mosome X or derived X involved in the CRLF2-r. It was identiﬁed in
patients with both IGH and P2RY8 involvement (4 vs. 5, respectively).
Real-time PCR conﬁrmed that the fusion was in-frame and was
expressed at the mRNA level (Supporting Information Figure 3C).
Sanger sequencing veriﬁed fusion of USP9X exon 31 to exon 2 of
DDX3X (Supporting Information Figure 3D). The DNA breakpoint
sequence from three patients consistently fell within intron 31 of
FIGURE 1 Comparative histograms of recurrent genetic
abnormalities in patients with CRLF2-r ALL. (A) Comparison of clinical
data between patients with IGH-CRLF2 (gray bars) and P2RY8-CRLF2
(black bars). (B) Comparison of genetic data between patients with
IGH-CRLF2 (gray bars) and P2RY8-CRLF2 (black bars). (C) Comparison
between CRLF2-r DS-ALL (black bars) and CRLF2-r non DS-ALL
patients (gray bars). * denotes those abnormalities where the incidence
between the two groups is statistically signiﬁcant
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USP9X (covering a 3.5 kb region) and intron 1 of DDX3X (covering a
2.1 kb region).
3.4 | Somatically acquired structural variants are rare,
while the incidence of kinase and JAK mutations is
high in CRLF2-r ALL
The somatic nature of 137 structural variants (SV) (6 tandem
duplication-, 104 deletion-, 14 inversion-, and 13 translocation-type
rearrangements) were validated, providing an average of 12.7 SV per
patient, irrespective of DS status (Figure 2; Supporting Information
Table 8; Supporting Information Figure 4). No novel recurrent rear-
rangements or fusion genes typical of B-other ALL were identiﬁed in
these 11 patients. There was no diﬀerence in the number of SV
between patients with IGH- and P2RY8-CRLF2 and also between
patients with and without DS.
WES from the same 11 patients detected 218 mutations, 187
point mutations, and 31 in/del events. Among the point mutations,
122 were predicted as possibly disease causing by PolyPhen-2 and
Mutation Taster (Figure 3; Supporting Information Table 9; Supporting
Information Figure 4). The average number of mutations was 19.8
(point mutations alone: 17) per patient, with no diﬀerence between
IGH- and P2RY8-CRLF2 (P5 .85) or those with or without DS (P5 .41).
In the majority of patients, at least half of the mutations were at variant
allele frequency (VAF) higher than 30%; only one patient (#11706) had
a higher number of mutations at a VAF of <20%. Recurrent mutations
were identiﬁed in CACNA1D, IKZF1, JAK2, IL7RA, NRAS, and USH2A
(n52 each). Ten patients had missense or nonsense point mutations in
genes with protein kinase functions (Table 1), with six patients harbor-
ing either a mutation or CNA in two or more kinase genes.
Targeted screening for JAK2 (n575) and JAK1 (n536) mutations
identiﬁed an incidence of 35% and 14%, respectively. There was no diﬀer-
ence in the number of JAK1 or JAK2mutations between IGH- and P2RY8-
CRLF2 (17% vs. 19%, P5 .46) or DS and non-DS patients (JAK2 Ex14,
44% vs. 35%, P5 .613; JAK1 Ex14, 17% vs. 11%, P51; Supporting Infor-
mation Table 5; Figure 1B,C). Due to selective screening of only exon 14
in the majority of patients, these numbers may represent an underesti-
mate of the true incidence of JAK1 and JAK2mutations in CRLF2-r ALL.
TABLE 1 Focal aberrations identiﬁed by SNP, paired-end and exome sequencing
Patient ID
B-cell
diﬀerentiation Cell cycle Kinase RAS
Cell
adhesion TP53
Other interesting
genes
P2RY8-CRLF2
9534 BTG1,
CDKN2AB
P2RY8-CRLF2,
JAK2, IL7R
NRAS LAMA1 CDKN2AB NFATC4, NCOA3
11538 ETV6, IKZF1,
PAX5
CDKN2AB,
FOXN3
P2RY8-CRLF2,
MAST4, STK38L,
RPS6KA5
NRAS ITGBL1,
USH2A
CDKN2AB CRIPAK, KDM4A,
SKIL, CCDC88C,
SMEK1, FBLN5,
CYP4A11
11706 ETV6 P2RY8-CRLF2,
CKMT1A, SPHKAP,
NBEA, PTPRT
PTPRT CREBBP, GLI1
20638 CDKN2AB P2RY8-CRLF2,
ACVRL1, IL7R
ITGA7, ANK2 CDKN2AB MLLT3, TUSC1,
TOPORS, DDX58,
APTX
20753 IKZF1, PAX5 CDKN2A P2RY8-CRLF2,
MAPK10
USH2A CDKN2A PPP2R3B, ZEDB1,
IL9R
21819 IKZF1, PAX5,
VPREB1
CDKN2AB,
MCC
P2RY8-CRLF2,
INSRR
NF1 CDKN2AB DDX6, CASZ1
21991 ETV6, VPREB1 CDKN2AB,
CCND3
P2RY8-CRLF2 CD38, NPNT CDKN2AB ARID5A, SEMA4C,
BTLA, TBL1XR1,
FHIT, PAXIP1
IGH-CRLF2
11543 EBF1, IKZF1 BTG1 IGH-CRLF2, JAK2,
TTBK1
NOX4, CHORDC1
19599 IKZF1, VPREB1 CDK13 IGH-CRLF2, JAK2,
CDK13
DST TOP3A, CREB5, TRL4,
CHN2, MPLKIP,
INHBA, GLI3,
TSC22D1
21245 EBF1, ETV6,
IKZF1, PAX5,
VPREB1
RB1, CDK6 IGH-CRLF2, JAK2,
ERBB4
CTNNA2 RB1 ABRA, BTLA, AFF1,
MEF2C, ADD3,
RUNX1
21470 ETV6, IKZF1,
VPREB1
IGH-CRLF2, CRLF2,
PTPN11, RHBDL2
PTPN11 ITGB7, LAMC2,
COL3A1,
CTTNBP2
MIR181B1, MIR181A1,
CADM1
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3.5 | Involvement of cell adhesion mutations in
CRLF2-r patients
WES data identiﬁed 1 somatic point mutation in a gene(s) involved in
cell adhesion in eight patients including; NPNT, ITGB7, COL3A1, ITGA7,
ITGBL1, DST, LAMC2, PTPRT, MAPK10, CCND3, CTNNA2, CTNND2, and
LAMA1 in single patients and USH2A in two patients (Table 1).
FIGURE 2 Acquired mutations and structural variations in CRLF2-r ALL. (A) Histogram representing the distribution of structural variants
(SV) in 11 patients with CRLF2-r ALL (x-axis, solid gray box depicts patients with P2RY8-CRLF2 and the dashed gray box, patients with IGH-
CRLF2), detected by paired-end sequencing and validated by FISH, MLPA, SNP arrays and/or PCR and subsequent Sanger sequencing for
breakpoint locations. Each patient is represented by a bar with the height of each bar being representative of the number of aberrations
present in that patients sample. Diﬀerent shades/patterns denote the diﬀerent types of SV that were detected. (B) Histogram representing
the distribution of coding mutations in same 11 patients with CRLF2-r ALL (x-axis, solid gray box depicts patients with P2RY8-CRLF2 and
the dashed gray box, IGH-CRLF2 patients), detected by whole exome sequencing. Each patient is represented by a bar with the height of
each bar being representative of the number of aberrations present in that patients sample. Diﬀerent shades/patterns denote the diﬀerent
types of coding mutations that were detected
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3.6 | Pathway analysis reveals deregulation in known
and novel pathways
Pathway analysis revealed those pathways likely to be deregulated due
to the presence of mutations (not including silent mutations), in/dels
and focal SV <1 Mb in size. The top ten pathways in which defective
genes were most frequently identiﬁed are depicted in Figure 3. Unsur-
prisingly, JAK-STAT involvement was seen in all patients. Other path-
ways included those involved in cancer, cytokine-cytokine interaction,
haematopoietic cell lineage and MAPK signaling. Interestingly, the focal
adhesion pathway was also recurrently involved.
4 | DISCUSSION
In this study investigating the genomic landscape of CRLF2-r ALL, we
have conﬁrmed the high incidence of CRLF2-r in DS-ALL, demon-
strated its co-existence with other primary chromosomal rearrange-
ments and enrichment of speciﬁc chromosomal gains and deletions of
IKZF1, BTG1, ADD3, SERP2, TSC22D1, SLX4IP, and PBX3. There were
signiﬁcant diﬀerences in CNA proﬁles between P2RY8-CRLF2 and IGH-
CRLF2 patients with an increased incidence of IKZF1, BTG1, and ADD3
deletions and a higher age at diagnosis being observed in the latter.
These disparities correlate with reported diﬀerences in outcome, where
for example older age and IKZF1 status drive the inferior prognosis
observed in adult IGH-CRLF2.14 A ﬁfth of CRLF2-r patients harbor a pri-
mary chromosomal abnormality with all but one being P2RY8-CRLF2,
suggesting a co-operating role for CRLF2 deregulation. Interestingly,
the sole patient with IGH-CRLF2 and a primary abnormality had the
BCR-ABL1 fusion in a separate clone.22 Collectively, these data do not
imply that IGH and P2RY8 are driving distinct subgroups but rather
that CRLF2-d may play a dual role as both a primary and co-operating
driver in ALL, with the latter being more prominent among P2RY8-
CRLF2 patients. This model is akin the BCR-ABL1 fusion, which
although predominatly a primary driver, has also been reported as a
secondary abnormality22,33. Independent pathway analysis of the aber-
ration proﬁle of IGH-CRLF2 and P2RY8-CRLF2 patients found enrich-
ment of all top ten pathways in the P2RY8-CRLF2 patients and only a
subset of pathways in IGH-CRLF2 patients. Previous studies have
reported the involvement of MAPK signaling in CRLF2-r ALL.34 This
pathway was not signiﬁcantly enriched in our IGH-CRLF2 patients;
however, this observation was based on only four patients and thus
requires further validation. WES identiﬁed a frequency of 20 mutations
per patient, similar to iAMP21-ALL,35 but higher than other
subgroups,23,36–38. The high VAF of kinase mutations suggested that
they were clonal and were likely acquired early in disease development.
Mutations in ERBB4, TTBK1, and STK38L occurred within the catalytic
domain with potential for constitutive activation. These mutations may
activate STAT5 (ERBB4), deregulate alternate pathways including,
FIGURE 3 Heatmap showing the frequency distribution of defective genes. The top ten pathways in which defective genes are most
frequently identiﬁed across 11 patients with CRLF2-r ALL are shown. The number in each cell represents numbers of defective genes
identiﬁed for particular pathways and patients, ranging from 0 (white) to 4 (dark gray). Total numbers of defective genes for each patient
are summarized in the bar chart on the top panel of the heatmap. Note that genes which are members of two or more pathways were
counted only once. Bar chart on the right panel summarises the total number of defective genes identiﬁed across the 11 patients for a
given pathway (KEGG pathways, with additional manually annotated genes underlined). # signiﬁcantly enriched (hypergeometric test P-
value< .05) in patients with P2RY8-CRLF2;  signiﬁcantly enriched in patients with IGH-CRLF2; * CNA of IKZF1;^IKZF1 point mutation
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NFKB and chromosome alignment pathways (TTBK1), or regulate the
Hippo signaling pathway (STK38L) by binding MOB kinase activators,
which have tumour suppressor roles. Taken together, these data imply
that CRLF2-r may deﬁne a distinct subgroup of B-other ALL.
For the ﬁrst time, we have implicated a role for USP9X and DDX3X
in CRLF2-r ALL. This USP9X-DDX3X fusion removes the ubiquitin
carboxyl-terminal hydrolase domain of USP9X, the promoter of DDX3X,
multiple regulatory elements, MIR7641-2 and non-coding RNAs. The
involvement of USP9X and DDX3X in cancer is known39–45 and another
translocation involving USP9X has been reported in a BCR-ABL1-like
ALL patient without CRLF2-r.4 In keeping with the emerging functions
of USP9X, its overexpression has been reported in B-ALL, suggesting
an oncogenic role.46 Knockdown of USP9X sensitises both predniso-
lone sensitive and resistant cell lines to glucocorticoid (GC)-induced
apoptosis, suggesting that reduced levels of USP9X may sensitise them
to prednisolone treatment.46
With the success of targeted approaches using tyrosine kinase
inhibitors (TKI) in BCR-ABL1-positive disease, there is clear rational to
apply similar targeted approaches to other ALL subtypes. CRLF2-r acti-
vate targetable pathways, including JAK-STAT, PI3K, and MAPK signal-
ing, and many groups are now assessing the eﬃcacy of inhibitors to
these pathways. The ﬁrst inhibitor to be tested in CRLF2-r ALL was the
JAK1/2 inhibitor, Ruxolitinb.47 While this study showed a response in
vivo, greater eﬀect was observed in JAK-activated, non-CRLF2-r ALL.
Evidence of resistance to type I inhibitors in model systems of B-ALL is
already driving the development of type II JAK inhibitors.48 Targeting
of mulitple pathways was an approach taken by Suryani et al, (2015) in
assessing the JAK inhibitor, AZD1480, alone and in combination with
the MEK inhibitor, Selumetinib.49 While this study showed a strong
anti-leukaemic eﬀect in vitro, only modest eﬀects were seen in vivo, an
important consideration for future preclinical testing, which highlights
the need to identify other common targets to provide further options
for more patients. In addition to JAK-STAT, we have identiﬁed several
deregulated pathways in CRLF2-r ALL, for example, focal adhesion sig-
naling, one which has not previously been implicated in this subtype of
ALL and was enriched in patients with both IGH- and P2RY8-CRLF2
ALL.
Mutations within genes controlling cell adhesion would seem to be
more relevant in solid tumours, where such lesions would provide cells
with a migratory and metastatic advantage. However, the presence of
such mutations within the primary site may be advantageous, where
small amounts of local movement can alter tumour growth and disper-
sal. In our study, eight patients (72%) had one or more focal adhesion
gene mutations; an incidence much higher than reported in other ALL
subtypes (ETV6-RUNX1, 12%23, Ph-like non-CRLF2-r, 15%4, low hypo-
diploidy, 5%37, high hyperdiploidy, 9.8%38, KTM2A-rearranged infant
ALL, 4.5%36). Mutated genes were speciﬁcally located within the
laminin-integrin-MAPK cell signaling axis. The laminins (LAMA1 and
LAMC2) and their receptor integrins (ITGA7, ITIBL1, and ITGB7) play a
central role in cell proliferation and tumour cell invasiveness through
their critical role in basement membrane adhesion.50 Although the
functional consequence of these mutations in CRLF2-r ALL remains to
be determined, when laminin binding integrin signaling is altered, it
activates downstream signaling kinases, such as FAK (focal adhesion
kinase) and JUN (MAPK10)-FOS, which impacts on cell proliferation
and migration in various cancers.51,52 In a recent study, the presence of
the Ikaros isoform 6 (IK6), IKZF1 haploinsuﬁciency or mutations in
BCR-ABL1-positive disease have been shown to increase expression of
adhesion molecules and increased transcription of FAK, rendering these
cells insensitive to tyrosine kinase inhibition.53 The application of inhib-
itors to FAK in patients with BCR-ABL1-positive ALL resulted in the
same abrogation of adhesion and self renewal programmes.54 Interest-
ingly, all 11 patients with sequencing data either showed mutation/
CNA of IKZF1 or a mutation within a focal adhesion gene. Our data
along with emerging literature in leukaemia highlight a role for the focal
adhesion pathway in CRLF2-r ALL.
In summary, we show clear clinical and genomic diﬀerences
between patients with IGH- and P2RY8-CRLF2. We describe these rear-
rangements in the presence of other established cytogenetic abnormal-
ities, suggesting a secondary role for CRLF2-r in some patients, akin to
BCR-ABL1 positive disease. However, due to low patient numbers, we
were unable to ascertain any impact of P2RY8-CRLF2 on the prognosis
of these patients. This co-occurrence needs to be further assessed in a
larger patient cohort. The treatment of patients across four independ-
ent trails precluded meaningful survival analysis between patients IGH-
and P2RY8-CRLF2. It is clear from our data that CRLF2-r ALL is hetero-
geneous, requiring a combination of genetic abnormalities in function-
ally relevant genes to co-operate with deregulated expression of
CRLF2. Although the functional relevance of some of the deletions and
mutations presented in this descriptive study are currently unknown,
there are pointers to activation of additional targetable pathways.
There is a clear requirement for studies addressing the biological eﬀect
of these aberrations, which together with the identiﬁcation of muta-
tions in cell adhesion genes and a high incidence of IKZF1 deletions
provide interesting targets for pre-clinical testing. Inhibitors to the focal
adhesion pathway, as one example, may provide an insight into a new
realistic therapeutic approach to improve outcome in CRLF2-r ALL.
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